From the Guidelines
There is no known interaction between pambezoic acid and evolocumab (Repatha), and they can generally be used together safely as they work through different mechanisms in the body. Evolocumab is a PCSK9 inhibitor that lowers LDL cholesterol by increasing the liver's ability to remove it from the bloodstream. Pambezoic acid is not a commonly recognized medication in standard medical practice, but if you're referring to a similar compound like bempedoic acid, it's an ACL inhibitor that inhibits cholesterol synthesis in the liver and increases LDL receptor density 1. However, you should always inform your healthcare provider about all substances you're taking, including supplements and over-the-counter products. This ensures your provider can monitor for any unexpected effects, especially since evolocumab is used for managing serious cardiovascular risk factors. If you experience any unusual symptoms after combining these substances, contact your healthcare provider promptly.
Some key points to consider:
- Evolocumab has demonstrated safety, efficacy, and cardiovascular outcomes benefits in FOURIER and ODYSSEY Outcomes trials 1.
- Bempedoic acid has been approved for the treatment of adults with ASCVD or HeFH who require additional lowering of LDL-C, and it may be especially useful in patients with statin-associated myalgias 1.
- The CLEAR Outcomes trial with bempedoic acid is currently in progress, and its results may provide further guidance on the use of this medication 1.
- It's essential to monitor patients for signs and symptoms of hyperuricemia, tendon rupture, and other potential adverse effects when using bempedoic acid or other nonstatin therapies 1.
In summary, while there is no known interaction between pambezoic acid and evolocumab, it's crucial to inform your healthcare provider about all substances you're taking and monitor for any unexpected effects. The combination of evolocumab and bempedoic acid or other nonstatin therapies may be considered in patients who require additional LDL-C lowering, but it's essential to weigh the potential benefits and risks and consider the individual patient's needs and medical history.
From the Research
Combination of Pambezoic Acid and Evolocumab
There are no research papers to assist in answering this question regarding the combination of pambezoic acid and evolocumab.
Available Information on Evolocumab
- Evolocumab is a PCSK9 inhibitor that significantly reduces low-density lipoprotein cholesterol (LDL-C) and improves the prognosis of patients with acute coronary syndrome (ACS) 2.
- It can be used in combination with statins and ezetimibe to strengthen lipid lowering in extremely high-risk coronary heart disease populations 2, 3.
- The pharmacodynamic effects of evolocumab on PCSK9 are rapid, with maximum suppression within 4 hours, and it reduces LDL-C by approximately 55-75% compared to placebo 4.
- Evolocumab has a favorable side effect profile and its self-administration at home appears to be safe and effective with appropriate training and instructions from a healthcare provider 5.
- Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia have been demonstrated, with consistently excellent LDL-C-lowering efficacy, tolerance, and safety throughout the longest-duration study of a PCSK9 inhibitor reported to date 6.
Note
No information is available on the combination of pambezoic acid and evolocumab, and the provided studies do not mention pambezoic acid.